All Type of News
KFDA rejects approval of Hanmi's sibutramine mesylate
The Korea Food and Drug Administration reacted negatively toward the approval of Hanmi's first generic version of Slimer capsule (sibutramine mesylate), first generic version of Reductil (sibutramine hydrochloride), a...
Penile rigidity as primary criteria in choice of impotence drug.
Impotence patients assessed the penile rigidity as the primary criteria in choice of an impotence drug according to a market survey conducted by Sinobate market research company assigned by Bayer-GSK.
The survey wa...
Hanmi's new amlodipine salt to get patent approval first in Korea.
The patent for amlodpine camsylate, a new salt of amlodpine and anti-hypertension drug, (brand name: Amodipine) has been approved for the first time in Korea under the patent registration No. 0452491.
Amlodpine ca...
Wholesalers worried Zuellig to exploit their advantageous position.
A loud complaint endlessly voiced out from the wholesalers circle as well as the drug companies where supplied their products as an out-sourcing arrangement that Zuellig made a lot of conflicts and troubles by their o...
Nifidipine may be most effective intervention for stable angina
Data presented at the October 16 Asia-Pacific symposium in Seoul showed that Bayer's Adalat (nifedipine) reduces the risk of coronary artery disease, explained Professor George Nole from the University of Zurich, depa...
Five-day workweek system may aggravate hospital management
The full implementation of a 40-hour work system per week at hospital is likely to aggravate hospital management, according to a local symposium.
Speaking at that symposium sponsored by the Korean College of Hospit...
Successful licensing needs smooth communication
To be successful in the global licensing front depends on the smooth communication between both firms, problem-solving networks and executives' strong determination and sustained follow-up endeavor after contract, sai...
KFDA mulls use of Bacchus-S as tradename of quasi-drug
A review on the permissible use of Bacchus-S as another tradename of quasi-drug, which is similar to Bacchus-F drink as a prescription drug, has been underway, according to the Korea Food and Drug Administration.
D...
Hanmi grew 33.4 percent in September
The value by Hanmi Pharm in the outpatient prescription sector in September grew 33.4 percent, to 18.7 billion won, compared with the same month of last year, due to strong demand of its first generic version of Norva...
Drugs proven of bio-equivalency to be well assessed its valueProf. Yoo Seon-dong of Sunkyunkwan Univ. College of Pharmacy advocated the substituted dispensing for generic drugs in his article contributed to a recent daily news paper, clai...
|
